The Impact of Solid Organ Transplantation on Sexual Dysfunction and Infertility in Older Men and Women: A Claims-Based Study

Transplantation linked to a 2.11% absolute drop in coded sexual dysfunction in men — statistically real, clinically modest

Journal: International Journal of Impotence Research | Published: 2025-07-08 | Type: Retrospective Cohort Study | PMID: 40629074 Authors: Obinna Obuekwe, Haley Clark, Gal Saffati, Tatyana Yatsenko, Laura Oscar-Thompson, Carlos Riveros, Akhil Muthigi (Houston Methodist Hospital / Baylor College of Medicine / Texas A&M, Houston TX) Funding/COI: No external funding. No conflicts of interest declared.

Summary

Researchers pulled insurance claims data on 64,932 U.S. adults who received heart, kidney, liver, lung, or pancreas transplants over the past 20 years and compared ICD-10-coded diagnoses of sexual dysfunction and infertility before and after surgery. Transplantation was associated with small but statistically significant reductions in sexual dysfunction, with men benefiting more than women. The one organ type most tied to diabetic sexual dysfunction — the pancreas — showed no improvement at all.

Claims

• Overall transplant cohort: absolute risk reduction (ARR) in sexual dysfunction of 1.40% (p < 0.001)
• Men: ARR 2.11% (p < 0.001) vs. women: ARR 0.20% (p = 0.035)
• By organ type, ARR for sexual dysfunction: heart 2.21%, kidney 1.42%, lung 1.24%, liver 0.74%
• Pancreas transplant: no significant change in sexual dysfunction
• Infertility: ARR 0.10% across all transplants (p = 0.013); no difference across organ types
• N = 64,932 adults (≥18 years), U.S. only, TriNetX database

Study Quality

This is a pre-post analysis with no control group, built on administrative claims data — which means sexual dysfunction and infertility are identified only when a provider codes an ICD-10 diagnosis. Claims-based capture of sexual dysfunction is notoriously incomplete: patients rarely volunteer it, and providers rarely code it in the context of a post-transplant visit focused on graft survival and immunosuppression. The apparent "reduction" post-transplant could reflect a coding artifact — patients and providers shifting clinical attention away from sexual health concerns once the primary organ crisis is resolved — rather than any true improvement in function.

The pre-post design without a control arm cannot distinguish transplant effect from natural history, regression to the mean, or changes in healthcare utilization patterns. No relative risk reductions or adjusted odds ratios appear in the abstract. The absolute numbers are small enough that methodological noise could plausibly explain them.

Red Flags

• No control group. A pre-post design cannot establish causality; we don't know what would have happened to these patients without transplantation over the same period.
• ICD-10 claims undercounting. Sexual dysfunction and infertility are dramatically under-coded in administrative data. Baseline prevalence is almost certainly suppressed, making the "reduction" hard to interpret.
• Absolute risk reductions are clinically modest. 2.11% for men, 0.20% for women. The infertility ARR of 0.10% is negligible.
• Pancreas transplant null finding is unexplained. Pancreatic disease (especially diabetes) is a primary driver of ED; the organ most mechanistically relevant shows zero benefit. The paper offers no explanation in the abstract.
• Title says "older men and women" but includes adults ≥18. Median age is unstated in the abstract; the framing doesn't match the inclusion criteria.
• No follow-up duration reported. The pre-post window is undefined, making it impossible to assess whether any improvement reflects short-term or durable change.
• No adjustment for immunosuppressant regimen. Several transplant medications directly affect sexual function; this confounding is unaddressed.

Strengths

• Large sample (64,932) across five organ types — the most comprehensive transplant sexual health dataset in claims literature.
• Appropriately sex-stratified analysis.
• Organ-type stratification reveals heterogeneous effects that a pooled analysis would bury.
• No industry funding and no declared conflicts.
• Uses TriNetX, a real-world dataset with reasonable national coverage.

Verdict

A large, unfunded, conflict-free study that asks a clinically important question most transplant trials ignore. The 64,932-patient sample and organ-type breakdown are genuine strengths, and the sex-stratified findings are at least hypothesis-generating. But the pre-post claims design can't establish that transplantation actually improved sexual function — it can only show that doctors coded it less afterward. The pancreas null finding undermines the biological story the authors seem to want to tell. Worth citing as the largest available estimate of post-transplant sexual dysfunction rates; not worth citing as evidence that transplantation restores sexual health.